← Eichor
Study identifier: NCT07036510 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery

Condition: Glaucoma · Ocular Hypertension  ·  Sponsor: EyeD Pharma

PhasePhase 1
Planned participants18
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery. The main questions it aims to answer are how safe are three different doses of the investigational drug is and how the body tolerates it. The study will also check: * how safely the implant is placed in and removed from the eye and how the body responds to the procedure, * if and the amount of Timolol released in the bloodstream, * if there is any positive effect on the pressure inside the eye.

This description comes directly from the study's public registry record.

Talk to the study team

EyeD Pharma  ·  +3242299000  ·  dpo@eyedpharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Panama Eye CenterPanama City, PanamaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07036510